Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent BioSolutions	$6.27 -5.1%	$5.61	$4.02 ▼ $15.10	$340.05M	2.1	1.79 million shs	742,766 shs
SNSS Sunesis Pharmaceuticals		$3.53	$1.12 ▼ $11.30	$96.26M	2.27	4.33 million shs	1.20 million shs
VSTM Verastem	$5.60 -4.8%	$6.66	$2.10 ▼ $9.10	$307.71M	0.85	1.15 million shs	1.30 million shs
XOMA XOMA	$23.85 -3.0%	$23.91	$18.35 ▼ $35.00	$285.41M	0.94	31,550 shs	35,900 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent BioSolutions	-5.22%	-5.65%	+9.91%	+9.24%	-0.87%
SNSS Sunesis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VSTM Verastem	-4.76%	-12.77%	-21.46%	-19.54%	+57.30%
XOMA XOMA	-3.05%	-5.54%	-10.81%	+16.74%	-4.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent BioSolutions	4.152 of 5 stars	3.5	2.0	0.0	4.6	0.6	2.5	1.3
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	3.2347 of 5 stars	4.5	2.0	0.0	0.0	1.6	2.5	0.6
XOMA XOMA	4.234 of 5 stars	3.5	2.0	0.0	3.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent BioSolutions	3.00	Buy	$14.33	128.78% Upside
SNSS Sunesis Pharmaceuticals	0.00	N/A	N/A	N/A
VSTM Verastem	3.00	Buy	$13.63	143.30% Upside
XOMA XOMA	3.00	Buy	$69.50	191.40% Upside

Current Analyst Ratings Breakdown

Latest SNSS, EBS, VSTM, and XOMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
4/17/2025	XOMA XOMA	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
4/1/2025	EBS Emergent BioSolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/28/2025	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00 ➝ $104.00
3/24/2025	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
3/24/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/21/2025	EBS Emergent BioSolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	VSTM Verastem	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent BioSolutions	$930.30M	0.37	$0.70 per share	8.92	$12.51 per share	0.50
SNSS Sunesis Pharmaceuticals	$2.07M	0.00	N/A	N/A	$1.42 per share	0.00
VSTM Verastem	$10M	30.77	N/A	N/A	$2.27 per share	2.47
XOMA XOMA	$13.05M	21.88	N/A	N/A	$7.72 per share	3.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent BioSolutions	-$760.50M	-$2.71	N/A	3.03	N/A	-18.55%	-9.91%	-3.31%	8/5/2025 (Estimated)
SNSS Sunesis Pharmaceuticals	-$23.33M	-$2.70	N/A	N/A	N/A	N/A	-179.05%	-72.27%	N/A
VSTM Verastem	-$87.37M	-$3.20	N/A	N/A	N/A	N/A	-332.73%	-73.97%	8/6/2025 (Estimated)
XOMA XOMA	-$40.83M	-$1.15	N/A	N/A	N/A	-151.34%	-24.95%	-9.64%	8/12/2025 (Estimated)

Latest SNSS, EBS, VSTM, and XOMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/13/2025	Q1 2025	XOMA XOMA	-$0.26	$0.06	+$0.32	$0.06	$6.75 million	$15.91 million
5/7/2025	Q1 2025	EBS Emergent BioSolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A
3/17/2025	Q4 2024	XOMA XOMA	-$0.29	-$0.46	-$0.17	-$0.46	$8.75 million	$8.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent BioSolutions	N/A	N/A	N/A	N/A	N/A
SNSS Sunesis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent BioSolutions	1.30	2.88	1.47
SNSS Sunesis Pharmaceuticals	N/A	7.74	7.74
VSTM Verastem	2.77	3.23	3.23
XOMA XOMA	1.28	7.52	7.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent BioSolutions	78.40%
SNSS Sunesis Pharmaceuticals	28.41%
VSTM Verastem	88.37%
XOMA XOMA	95.92%

Insider Ownership

Company	Insider Ownership
EBS Emergent BioSolutions	3.20%
SNSS Sunesis Pharmaceuticals	4.22%
VSTM Verastem	2.10%
XOMA XOMA	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent BioSolutions	2,420	54.28 million	53.53 million	Optionable
SNSS Sunesis Pharmaceuticals	24	18.09 million	N/A	Optionable
VSTM Verastem	50	54.95 million	43.53 million	Optionable
XOMA XOMA	10	11.97 million	10.94 million	Optionable

SNSS, EBS, VSTM, and XOMA Headlines

Recent News About These Companies

XOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street Zen

June 14 at 2:16 AM | marketbeat.com

XOMA (NASDAQ:XOMA) Stock Rating Upgraded by Wall Street Zen

June 2, 2025 | marketbeat.com

HC Wainwright Issues Positive Outlook for XOMA Earnings

May 31, 2025 | marketbeat.com

Positive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy Rating

May 29, 2025 | tipranks.com

XOMA's (XOMA) "Buy" Rating Reaffirmed at HC Wainwright

May 29, 2025 | marketbeat.com

XOMA boosts stake in anti-CD38 antibody with $30 million deal

May 28, 2025 | thepharmaletter.com

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 28, 2025 | benzinga.com

XOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating

May 28, 2025 | tipranks.com

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025 | globenewswire.com

Woodline Partners LP Acquires 60,927 Shares of XOMA Co. (NASDAQ:XOMA)

May 27, 2025 | marketbeat.com

Insider Selling: XOMA Co. (NASDAQ:XOMA) CEO Sells 25,637 Shares of Stock

May 22, 2025 | insidertrades.com

Bvf Partners L. P/Il Sells 392,723 Shares of XOMA Co. (NASDAQ:XOMA) Stock

May 21, 2025 | insidertrades.com

Major Shareholder Sells Massive Chunk of Xoma Stock!

May 20, 2025 | tipranks.com

Stonepine Capital Management LLC Reduces Stock Holdings in XOMA Co. (NASDAQ:XOMA)

May 20, 2025 | marketbeat.com

Leerink Partnrs Analysts Boost Earnings Estimates for XOMA

May 20, 2025 | marketbeat.com

XOMA Royalty First Quarter 2025 Earnings: Beats Expectations

May 15, 2025 | finance.yahoo.com

XOMA Royalty Reports Strong Q1 2025 Results

May 14, 2025 | tipranks.com

XOMA Royalty: Q1 Earnings Snapshot

May 13, 2025 | sfgate.com

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

May 13, 2025 | finance.yahoo.com

XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates

May 13, 2025 | zacks.com

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSS, EBS, VSTM, and XOMA Company Descriptions

Emergent BioSolutions NYSE:EBS

$6.26 -0.34 (-5.08%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$6.24 -0.02 (-0.32%)

As of 06/13/2025 07:56 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Sunesis Pharmaceuticals NASDAQ:SNSS

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Verastem NASDAQ:VSTM

$5.60 -0.28 (-4.76%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.84 +0.24 (+4.20%)

As of 06/13/2025 07:45 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

XOMA NASDAQ:XOMA

$23.80 -0.80 (-3.25%)

As of 06/13/2025 04:00 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time